Angiopoietin-2 May Be Involved in the Resistance to Bevacizumab in Recurrent Glioblastoma

Marianne Labussière, Caroline Cheneau, Claudia Prahst, Jaime Gállego Pérez-Larraya, Patrizia Farina, Giuseppe Lombardi, Karima Mokhtari, Amithys Rahimian, Jean Yves Delattre, Anne Eichmann, Marc Sanson

Research output: Contribution to journalArticlepeer-review


Despite encouraging response rate of bevacizumab (BVZ) in recurrent glioblastoma, many patients do not respond to this schedule and most of the responders develop an early relapse. Plasma concentrations of VEGF, PlGF, Ang2, and sTie2 were assessed by ELISA before and during BVZ treatment in seventy patients. Baseline levels of VEGF-A, and PlGF were higher in patients than in healthy volunteers, whereas no difference was found for Ang2, and sTie2. No biomarker at baseline was associated with response, PFS or OS. At recurrence, the authors observed an increase of Ang2 suggesting that Ang2/sTie2 could be involved in the resistance to BVZ.

Original languageEnglish
Pages (from-to)39-44
Number of pages6
JournalCancer Investigation
Issue number1
Publication statusPublished - Jan 2 2016


  • Angf
  • bevacizumab
  • Glioblastoma
  • plasma biomarkers

ASJC Scopus subject areas

  • Cancer Research
  • Oncology


Dive into the research topics of 'Angiopoietin-2 May Be Involved in the Resistance to Bevacizumab in Recurrent Glioblastoma'. Together they form a unique fingerprint.

Cite this